Pei Gu, Xiu Jin, Xue Li, Yan-Qing Wu, Fu-Qiang Mao
{"title":"[少药肝草汤治疗奥氮平所致高泌乳素血症]。","authors":"Pei Gu, Xiu Jin, Xue Li, Yan-Qing Wu, Fu-Qiang Mao","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>Objective To observe the efficacy and safety of Shaoyao Gancao Decoction (SGD) in treating olanzapine induced hyperprolactinemia. Methods Totally 120 schizophrenia patients who took Olanzapine Tablet (OT) were assigned to the treatment group and the control group by random number table, 60 in each group. All patients took OT. Those in the treatment group additionally took SGD. The ther- apeutic course for all was 8 weeks. Serum levels of prolactin were measured before treatment and at the end of week 2, 4, and 8 after treatment. The spiritual symptoms of patients were assessed by Positive and Negative Syndrome Scale (PANSS) before treatment and at the end of week 8 after treatment. Adverse reactions were assessed using Treatment Emergent Symptom Scale (TESS) before treatment and at the end of week 8 after treatment. Results Compared with before treatment in the same group, ser- um levels of prolactin were significantly reduced in the treatment group at the end of week 4 and 8 after treatment (P <0. 05). There was no statistical difference in serum levels of prolactin in the control group among each time points (P > 0. 05). Compared with the control group, serum levels of prolactin de- creased significantly in the treatment group at the end of week 4 and 8 after treatment (P <0. 01). There was no statistical difference in PANSS between the two groups at the end of week 8 after treatment (P> 0. 05). Adverse reactions occurred in 5 cases (943%) of the treatment group and 4 cases (7. 14%) in the control group. They were manifested as insomnia, headache, constipation, and incapability of sitting quietly. There was no statistical difference in adverse reaction between the two groups (P'>0. 05). Con- clusions SGD could effectively improve olanzapine-induced hyperprolactinemia, and had no obvious effect on psychotic symptoms. It showed no obvious adverse reactions.</p>","PeriodicalId":10107,"journal":{"name":"中国中西医结合杂志","volume":"36 12","pages":"1456-1459"},"PeriodicalIF":0.0000,"publicationDate":"2016-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"[Treatment of Olanzapine-induced Hyperprolactinemia by Shaoyao Gancao Decoction].\",\"authors\":\"Pei Gu, Xiu Jin, Xue Li, Yan-Qing Wu, Fu-Qiang Mao\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Objective To observe the efficacy and safety of Shaoyao Gancao Decoction (SGD) in treating olanzapine induced hyperprolactinemia. Methods Totally 120 schizophrenia patients who took Olanzapine Tablet (OT) were assigned to the treatment group and the control group by random number table, 60 in each group. All patients took OT. Those in the treatment group additionally took SGD. The ther- apeutic course for all was 8 weeks. Serum levels of prolactin were measured before treatment and at the end of week 2, 4, and 8 after treatment. The spiritual symptoms of patients were assessed by Positive and Negative Syndrome Scale (PANSS) before treatment and at the end of week 8 after treatment. Adverse reactions were assessed using Treatment Emergent Symptom Scale (TESS) before treatment and at the end of week 8 after treatment. Results Compared with before treatment in the same group, ser- um levels of prolactin were significantly reduced in the treatment group at the end of week 4 and 8 after treatment (P <0. 05). There was no statistical difference in serum levels of prolactin in the control group among each time points (P > 0. 05). Compared with the control group, serum levels of prolactin de- creased significantly in the treatment group at the end of week 4 and 8 after treatment (P <0. 01). There was no statistical difference in PANSS between the two groups at the end of week 8 after treatment (P> 0. 05). Adverse reactions occurred in 5 cases (943%) of the treatment group and 4 cases (7. 14%) in the control group. They were manifested as insomnia, headache, constipation, and incapability of sitting quietly. There was no statistical difference in adverse reaction between the two groups (P'>0. 05). Con- clusions SGD could effectively improve olanzapine-induced hyperprolactinemia, and had no obvious effect on psychotic symptoms. It showed no obvious adverse reactions.</p>\",\"PeriodicalId\":10107,\"journal\":{\"name\":\"中国中西医结合杂志\",\"volume\":\"36 12\",\"pages\":\"1456-1459\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2016-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"中国中西医结合杂志\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"中国中西医结合杂志","FirstCategoryId":"3","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
[Treatment of Olanzapine-induced Hyperprolactinemia by Shaoyao Gancao Decoction].
Objective To observe the efficacy and safety of Shaoyao Gancao Decoction (SGD) in treating olanzapine induced hyperprolactinemia. Methods Totally 120 schizophrenia patients who took Olanzapine Tablet (OT) were assigned to the treatment group and the control group by random number table, 60 in each group. All patients took OT. Those in the treatment group additionally took SGD. The ther- apeutic course for all was 8 weeks. Serum levels of prolactin were measured before treatment and at the end of week 2, 4, and 8 after treatment. The spiritual symptoms of patients were assessed by Positive and Negative Syndrome Scale (PANSS) before treatment and at the end of week 8 after treatment. Adverse reactions were assessed using Treatment Emergent Symptom Scale (TESS) before treatment and at the end of week 8 after treatment. Results Compared with before treatment in the same group, ser- um levels of prolactin were significantly reduced in the treatment group at the end of week 4 and 8 after treatment (P <0. 05). There was no statistical difference in serum levels of prolactin in the control group among each time points (P > 0. 05). Compared with the control group, serum levels of prolactin de- creased significantly in the treatment group at the end of week 4 and 8 after treatment (P <0. 01). There was no statistical difference in PANSS between the two groups at the end of week 8 after treatment (P> 0. 05). Adverse reactions occurred in 5 cases (943%) of the treatment group and 4 cases (7. 14%) in the control group. They were manifested as insomnia, headache, constipation, and incapability of sitting quietly. There was no statistical difference in adverse reaction between the two groups (P'>0. 05). Con- clusions SGD could effectively improve olanzapine-induced hyperprolactinemia, and had no obvious effect on psychotic symptoms. It showed no obvious adverse reactions.